Trastuzumab biosimilar (Samsung Bioepis)

曲妥珠单抗生物类似药（三星Bioepis）

Report date: 2023/04/10 14:28:36

Base Information

Drug NameTrastuzumab biosimilar (Samsung Bioepis)
Drug Alias Nametrastuzumab-dttb曲妥珠单抗生物仿制药（三星Bioepis）SamfenetOntruzantSB-3 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsStomach NeoplasmsBreast Neoplasms
Global Approved IndicationsStomach NeoplasmsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/11/15
Country/TerritoryCzechiaUnited StatesGermany +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co IncSamsung Bioepis Nl BvSamsung Bioepis Co Ltd
Inactive CompaniesAffamed Therapeutics Ltd
Active IndicationsStomach NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksWikipediaDrugBankKEGG